|本期目录/Table of Contents|

[1]邱 静,黄 庆.HJURP在肺腺癌组织中高表达并与患者不良预后相关性[J].中华肺部疾病杂志,2023,(04):495-499.[doi:10.3877/cma.j.issn.1674-6902.2023.04.009 ]
　Qiu Jing,Huang Qing..Hight expression of HJURP in lung adenocarcinoma and related with poor prognosis[J].,2023,(04):495-499.[doi:10.3877/cma.j.issn.1674-6902.2023.04.009 ]
点击复制

HJURP在肺腺癌组织中高表达并与患者不良预后相关性(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2023年04期
页码:
495-499
栏目:
论著
出版日期:
2023-08-20

文章信息/Info

Title:
Hight expression of HJURP in lung adenocarcinoma and related with poor prognosis
作者:
邱 静1; 黄 庆2
400037 重庆,陆军(第三)军医大学第二附属医院药剂科1、医院临床医学研究中心2
Author(s):
Qiu Jing1;  Huang Qing2.
1Department of Pharmacy, The Second Affiliated Hospital, Army Medical University, Chongqing 400037, China; 2Clinical Medical Research Center, The Second Affiliated Hospital, Army Medical University, Chongqing 400037, China
关键词:
肺腺癌;  Holliday交叉识别蛋白;  预后;  生物信息学
Keywords:
LUAD;  HJURP;  Prognosis;  Bioinformatics
分类号:
R734.2
DOI:
10.3877/cma.j.issn.1674-6902.2023.04.009
摘要:
目的 分析Holliday交叉识别蛋白(holliday junction recognition protein, HJURP)在肺腺癌(lung adenocarcinoma, LUAD)中的表达水平及其在预后评估中的价值。方法 从公共数据库TCGA(The Cancer Genome Atlas)和GEO(Gene Expression Omnibus)下载LUAD患者的基因表达和临床数据,利用R语言软件分析HJURP的表达水平; 从HPA(Human Protein Atlas)数据库下载LUAD患者的HJURP蛋白表达数据; 应用ssGSEA算法进行免疫浸润分析; ROC曲线(receiver operating characteristic curve)、Kaplan-Meier分析、单因素和多因素COX回归分析、列线图和校准曲线评价HJURP在肿瘤预后评估中的价值。结果 LUAD中HJURP的表达水平显著高于癌旁组织(P<0.001); 免疫浸润分析结果显示HJURP与嗜酸性粒细胞、肥大细胞富集评分呈负相关(P<0.001),与活化CD4 T细胞富集评分呈正相关(P<0.001); 在预后分析结果中,HJURP对LUAD预后灵敏度高,HJURP高表达的患者总生存率较差。COX回归分析显示,HJURP表达是总生存率的风险因素。结论 HJURP在LUAD中表达异常上调,并与不良预后显著相关,提示HJURP可能为LUAD潜在的诊断标志物和治疗靶点。
Abstract:
Objective To investigate the expression leve land prognostic significance of Holliday cross recognition protein(HJURP)in lung adenocarcinoma(LUAD). Methods Gene expression and clinical data of LUAD patients were downloaded from the public databases TCGA(The Cancer Genome Atlas)and GEO(Gene Expression Omnibus), the expression levels of HJURP were analyzed by R language software. HJURP protein expression date of LUAD patients were downloaded from the HPA(Human Protein Atlas). SsGSEA algorithm was used to analyze the immune infiltration. Then, ROC curves, Kaplan-Meier analysis, univariate and multivariate COX regression analysis, nomograms and calibration curves were applied to evaluate the association between HJURP expression and clinical prognosis. Results The expression of HJURP was significantly higher in LUAD than in adjacent tissues(P<0.001). Immune filtration analysis showed that HJURP was negatively correlated with eosinophils and mastcells(P<0.001), and positively correlated with activated CD4 T cells(P<0.001). In the results of the clinical prognosis analysis, HJURP was highly sensitive to the prognosis of LUAD, and patients with high HJURP expression had poor overall survival. COX regression analysis showed that the expression of HJURP was an independent risk factor for the overall survival rate. Conclusion HJURP is overexpressed in LUAD and is significantly associated with poor prognosis, suggesting the potential of HJURP as a diagnostic marker and therapeutic target for LUAD.

参考文献/References:

1 钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
2 Denisenko TV, Budkevich IN, Zhivotovsky B. Cell death-based treatment of lung adenocarcinoma[J]. Cell Death Dis, 2018, 9(2): 117.
3 Bade BC, Dela Cruz CS. Lung cancer 2020: Epidemiology, etiology,and prevention[J]. Clin Chest Med, 2020, 41(1): 1-24.
4 Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
5 Osmani L, Askin F, Gabrielson E, et al. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma(NSCLC): Moving from targeted therapy to immunotherapy[J]. Semin Cancer Biol, 2018, 52(Pt 1): 103-109.
6 Chalela R, Curull V, EnríquezC, et al. Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy[J]. J Thorac Dis, 2017, 9(7): 2142-2158.
7 Xu JY, Zhang CC, Wang X, et al. Integrative proteomic characterization of human lung adenocarcinoma[J]. Cell, 2020, 182(1): 245-261.
8 Oberndorfer F, Müllauer L. Molecular pathology of lung cancer: current status and perspectives[J]. Curr Opin Oncol, 2018, 30(2): 69-76.
9 王洪武, 金发光. 晚期非小细胞肺癌多域整合治疗策略[J/CD]. 中华肺部疾病杂志(电子版), 2022, 15(4): 457-461.
10 Dunleavy EM, Roche D, Tagami H, et al. HJURPis a cell-cycle-dependent maintenance and deposition factor of CENP-A at centromeres[J]. Cell, 2009, 137(3): 485-497.
11 Müller S, Montes de Oca R, Lacoste N, et al. Phosphorylation and DNA Binding of HJURP Determine Its Centromeric Recruitment and Function in CenH3CENP-A Loading[J]. Cell Rep, 2014, 8(1): 190-203.
12 Wei Y, Ouyang GL, Yao WX, et al. Knockdown of HJURP inhibits non-small cell lung cancer cell proliferation, migration, and invasion by repressing Wnt/β-catenin signaling[J]. Eur Rev Med Pharmacol Sci, 2019, 3(9): 3847-3856.
13 Montes de Oca R, Gurard-Levin ZA, Berger F, et al. The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma[J]. Mol Oncol, 2015, 9(3): 657-674.
14 Gao S, Zhou XQ, Wu Q, et al. Effects of holliday junction-recognition protein-mediated C-Jun N-terminal kinase/ signal transducer and activator of transcription 3 signaling pathway on cell proliferation, cell cycle and cell apoptosis in bladder urothelial carcinoma[J]. Tohoku J Exp Med, 2023, 259(3): 209-219.
15 Valente V, Serafim RB, de Oliveira LC, et al. Modulation of HJURP (Holliday junction-recognizing protein)levels is correlated with glioblastoma cells survival[J]. PLoS One, 2013, 8(4): e62200.
16 Sakkal S, Miller S, Apostolopoulos V, et al. Eosinophils in cancer: Favourable or unfavourable?[J].Curr Med Chem, 2016, 23(7): 650-666.
17 Carretero R, Sektioglu IM, Garbi N, et al. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+)T cells[J]. Nat Immunol, 2015, 16(6): 609-617.
18 Lai WF, Xie HF, Liu YT, et al. Human pluripotent stem cell-derived eosinophils reveal potent cytotoxicity against solid tumors[J]. Stem Cell Reports, 2021, 16(7): 1697-1704.
19 Komi DEA, Redegeld FA. Role of mast cell sinshaping the tumor microenvironment[J]. Clin ReAllergy Immuno, 2020, 58(3): 313-325.
20 Plotkin JD, Elias MG, Fereydouni M, et al. Human mastcells from adipose tissue target and induce apoptosis ofbreast cancer cells[J]. Front Immunol, 2019, 10: 138.
21 DaSilva JM, Moreira Dos Santos TP, Sobral LM, et al. Relevance of CCL3/CCR5 axis in oral carcinogenesis[J]. Oncotarget, 2017, 8(31): 51024-51036.
22 Xie F, Liu LB, Shang WQ, et al. The infifiltration and functional regulation of eosinophils induced by TSLP promote the proliferation of cervical cancer cell[J]. Cancer Lett, 2015, 364(2): 106-117.
23 Lv YP, Zhao YL, Wang XH, et al. Increased intratumoral mast cells foster immune suppression and gastric cancer progression through TNF-α-PD-L1 pathway[J]. J Immunother Cancer, 2019, 7(1): 54.
24 Xiao H, He MD, Xie GG, et al. The release of tryptase frommast cells promote tumor cell metastasis via exosomes[J]. BMC Cancer, 2019, 19(1): 1015.
25 Varricchi G, Galdiero MR, Loffredo S, et al. Eosinophils: The unsung heroes in cancer?[J]. Oncoimmunology, 2018, 7(2): e1393134.
26 Sammarco G, Varricchi G, Ferraro V, et al. Mast cells, angiogenesis and lymphangiogenesis in human gastric cancer[J]. Int J Mol Sci, 2019, 20(9): 2106.

备注/Memo

备注/Memo:
收稿日期:2023-02-17)
通信作者: 黄 庆, Email: 18375952140@163.com

更新日期/Last Update: 2023-08-20